XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 28, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name EyePoint Pharmaceuticals, Inc.    
Entity Central Index Key 0001314102    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Trading Symbol EYPT    
Entity Common Stock, Shares Outstanding   68,728,760  
Entity Public Float     $ 450.8
Entity Emerging Growth Company false    
Entity Small Business true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity File Number 000-51122    
Entity Tax Identification Number 26-2774444    
Entity Address, Address Line One 480 Pleasant Street    
Entity Address, City or Town Watertown    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02472    
City Area Code (617)    
Local Phone Number 926-5000    
Document Annual Report true    
Document Transition Report false    
Entity Incorporation, State or Country Code DE    
Title of 12(b) Security Common Stock, par value $0.001    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Entity Current Reporting Status Yes    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 34    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of EyePoint Pharmaceuticals, Inc. and subsidiaries (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of comprehensive loss, stockholders' equity, and cash flows, for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

    
Auditor Name Deloitte & Touche LLP    
Auditor Location Boston, Massachusetts    
Documents Incorporated by Reference

Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant’s proxy statement for the 2025 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant’s fiscal year ended December 31, 2024.

r